T he current perspective demonstrated that rats treated with ZnO-RSV NPs showed no noticeable differences compared to the control group. However, ZnO-RSV NPs ameliorated LFX-induced detrimental alterations in semen biomarkers, serum testosterone, FSH, LH, testicular antioxidants, histopathology, and immunoreactivity of protein markers. The administration of ZnO-RSV NPs for protection against LFX had better outcomes than its use as a form of treatment. The favorable impacts of ZnO-RSV NPs may result from its antioxidant activity, which counteracts LFX-induced oxidative stress, inhibits BCL-2 protein, and restores BAX protein immuno reactivity. ZnO-RSV NPs may be a suitable choice for dealing with the fertility problems associated with LFX.